Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Magnite, the largest independent sell-side advertising company, announced it will release its Q3 2026 financial results after market close on November 4, 2026, followed by a conference call to discuss performance and outlook.
Revolution Medicines has commenced patient treatment in the Phase 3 RASolute 309 trial to evaluate the efficacy and safety of combining RASONQUE (daraxonrasib) with zoldonrasib as a first-line therapy for metastatic RAS G12D pancreatic adenocarcinoma. The trial compares this novel targeted combination against the current standard-of-care chemothera…
Baird Medical Investment Holdings Ltd. reported significant progress in Q3 2026, including international market expansion, introduction of irreversible electroporation technology through a strategic partnership, and enhanced physician training programs. The company also presented its growth strategy at the H.C. Wainwright Global Investment Conferen…
4D Molecular Therapeutics announced it will host an Investor Day on October 21, 2026, in New York City, featuring presentations and discussions with leading retinal experts. The event will highlight advancements in the company's lead product candidate 4D-150, a durable therapy targeting VEGF-driven retinal vascular diseases like wet age-related mac…
Trasteel Holding S.A., a global steel trading and industrial group, has assumed operational control of the La Magona d’Italia steel plant in Piombino, Italy, through newly formed Trasteel Magona S.r.l. The plant, operating under a lease agreement until the end of 2027, will be gradually restarted with a goal to reach full production capacity of ove…
PMV Pharmaceuticals appoints Matt Eckler, Ph.D., to its Board of Directors, bringing over 20 years of healthcare investment and scientific research experience. The company is preparing for an NDA submission in early 2027 for rezatapopt, a first-in-class small molecule targeting p53 mutations in platinum-resistant ovarian cancer. Rezatapopt has FDA …
Radiopharm Theranostics successfully completed an End-of-Phase 2 meeting with the FDA regarding RAD101, a novel imaging agent targeting fatty acid synthase for detecting brain metastases. The productive interaction clarified the regulatory pathway, enabling the company to proceed with Phase 3 clinical trial preparations. The FDA's feedback is expec…
MindWave Innovations Inc. USA, a subsidiary of Apimeds Pharmaceuticals US (NYSE American: APUS), signed a 2-year master maintenance and service agreement with BlockAssure Inc. to develop, deploy and operate AssureChain, a dedicated blockchain subnet for insurance and reinsurance operations. The contract includes development fees and a 20% allocatio…
Rezolve Ai has entered a worldwide reseller agreement with Mastercard, authorizing Mastercard to market and sell Rezolve Ai's AI-powered commerce technology on a non-exclusive basis. This partnership aims to accelerate international growth and adoption of Rezolve Ai's software solutions that enhance conversational commerce, product discovery, perso…
CoreCivic, Inc. announced it will release its third quarter 2026 financial results on November 4, 2026, followed by a live conference call on November 5. The company provides government solutions including correctional, detention, and reentry facility management and services, and has been a longstanding government partner.
Celcuity Inc. announced it will present new clinical trial data at the European Society for Medical Oncology (ESMO) Congress 2026. The presentations will cover updated results from the VIKTORIA-1 Phase 3 trial of gedatolisib in hormone receptor positive, HER2-negative advanced breast cancer and findings from trials in metastatic castration-resistan…
Lisata Therapeutics, through its subsidiary Marea Therapeutics, has dosed the first patient in a Phase 2 clinical trial for MAR002, a novel monoclonal antibody designed to treat acromegaly by blocking growth hormone receptors. The therapy demonstrated promising Phase 1 results with durable IGF-1 suppression and potentially infrequent dosing compare…
Pacira BioSciences announced an exclusive agreement with Molteni Farmaceutici to commercialize EXPAREL, its non-opioid long-acting local analgesic for postsurgical pain, across the European Union and United Kingdom. This strategic partnership aligns with Pacira's 5x30 growth strategy, aims to enhance patient access to opioid-sparing therapies, and …
Rani Therapeutics announced that its RaniPill® Capsule™ platform technology has been accepted into the FDA's Emerging Technology Program (ETP). This acceptance facilitates early and direct engagement with the FDA to support the development of their novel oral delivery system for biologics, potentially revolutionizing drug administration by replacin…
vTv Therapeutics has completed enrollment of 166 patients in its Phase 3 CATT1 study evaluating cadisegliatin, a novel oral glucokinase activator with Breakthrough Therapy designation, aimed at reducing hypoglycemia and improving glycemic control in type 1 diabetes patients. Topline results are expected in mid-2027, advancing cadisegliatin towards …
Prime Medicine has initiated dosing in its global Phase 1/2 clinical trial of PM577a, an in vivo Prime Editing therapy aimed at correcting the H1069Q mutation causing Wilson disease. This one-time gene editing treatment is designed to address the genetic root of Wilson disease, a rare progressive disorder lacking curative therapies. The U.S. FDA ha…
Kratos Defense & Security Solutions, Inc. announced that it has secured multiple contracts totaling more than $100 million to develop advanced prototype systems and cyber capabilities for space intelligence data to support joint military operations. These technologies will enhance capabilities in radio frequency signal collection, operational intel…
TELA Bio announced FDA 510(k) clearance for its Liora Monofilament Scaffold, a fully resorbable surgical mesh for soft tissue reinforcement. This product represents the company's first fully synthetic device developed and manufactured in-house at their Malvern facility. The clearance is expected to broaden TELA Bio’s presence in the soft tissue rec…
AGM Group Holdings Inc., a Nasdaq-listed integrated technology company specializing in high-performance hardware and blockchain ASIC chip development, announced the successful closing of an $11 million private placement. The funds will be used for corporate purposes including working capital, project development, and strategic initiatives to suppor…
CCC Intelligent Solutions is positioned to convert AI initiatives into recurring revenue through embedded workflows across claims, repair and underwriting. With execution improving, a clear product roadmap and a still-reasonable entry point, we favor a long trade that targets a re-rating as ARR and margins begin compounding.
Polyrizon Ltd., a clinical-stage biotech specializing in intranasal hydrogels, has filed a new U.S. divisional patent application to further protect its proprietary mucoadhesive polymer technology. This technology underpins the company's nasal drug delivery platform, potentially enabling local and systemic delivery of therapeutic agents via nasal m…
Applied Digital (APLD) just turned the next phase of Polaris Forge 1 to ready-for-service, bringing operational capacity to 250 MW with a 400 MW buildout planned. The market has punished APLD for heavy capital spend and near-term losses, but successful capacity ramp and revenue conversion over the next 6-12 months could justify P/S multiple expansi…
Crescent Biopharma announced FDA clearance of the IND application for CR-002, a topoisomerase inhibitor antibody-drug conjugate targeting PD-L1, intended to treat advanced solid tumors. The company plans to launch the global Phase 1/2 APOLLO trial in Q4 2026, enrolling approximately 200 patients with various solid tumors such as NSCLC and HNSCC, wi…
Stardust Power Inc. has established a new office in Houston, Texas, to serve as a project execution hub supporting the development of its lithium refinery in Muskogee, Oklahoma. This strategic expansion leverages Houston's energy sector expertise and infrastructure to accelerate the refinery build, enhancing the company's operational footprint duri…
Nexus Advanced Technologies Inc. announced an agreement with Anson Funds to restructure convertible notes and warrants. This agreement aims to simplify the company's capital structure by fixing conversion prices, eliminating anti-dilution provisions, and enabling a warrant exchange that will dilute existing shareholders but retire adjustment provis…
